N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea

Cat. No.: HY-101708 Purity: 99.73%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

N-[(1R)-4-[(Aminoiminomethyl)amino]-1-[[[(1R)-1-(4-hydroxyphenyl)ethyl]amino]carbonyl]butyl]-α-phenylbenzeneacetamide is an anticonvulsant agent with potential for the treatment of generalized tonic-clonic and partial seizures.

For research use only. We do not sell to patients.

N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea Chemical Structure

CAS No. : 97627-24-2

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 116	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 116	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 105	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 175	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 350	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 560	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 900	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

In Vivo

Compound shows anticonvulsant activity at 30 mg/kg in the initial tests with no signs of ataxia until 300 mg/kg. The activity seen with 30 mg/kg 37 is still present 4 h postdose. Compound is effective against seizures induced by maximal electroshock but does not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that Compound would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound is selected for clinical trials^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

261.71

Formula

C₁₃H₁₂ClN₃O

CAS No.

97627-24-2

Appearance

Solid

Color

White to off-white

SMILES

O=C(NC1=CC=NC=C1)NC2=C(C)C=CC=C2Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (477.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.8210 mL	19.1051 mL	38.2102 mL
5 mM	0.7642 mL	3.8210 mL	7.6420 mL
10 mM	0.3821 mL	1.9105 mL	3.8210 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (7.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.73%

Select Batch:

Data Sheet (273 KB) SDS (252 KB)

COA (247 KB) HNMR (246 KB) LCMS (268 KB)

Handling Instructions (2659 KB)

References

[1]. Pavia MR, et al. N-Phenyl-N'-pyridinylureas as Anticonvulsant Agents. J. Med. Chem. 1990,33, 854-861

Animal Administration
^[1]

Mice: Five mice are tested at each of three doses (30,100, and 300 mg/kg) and three times (0.5, 2, and 4 h). The mice are subjected to electrical current delivered through ear clips for 0.2 s (90 mA, 1-ms monophasic pulses at 100 Hz). This current strength is approximately 4 times that required to produce seizures in 99% of mice and reliably produce seizures in 100% of control mice. Prevention of tonic hind limb extension is taken as an anticonvulsant effect. Behavioral side effects are measured in mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Pavia MR, et al. N-Phenyl-N'-pyridinylureas as Anticonvulsant Agents. J. Med. Chem. 1990,33, 854-861

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.8210 mL	19.1051 mL	38.2102 mL	95.5256 mL
	5 mM	0.7642 mL	3.8210 mL	7.6420 mL	19.1051 mL
	10 mM	0.3821 mL	1.9105 mL	3.8210 mL	9.5526 mL
	15 mM	0.2547 mL	1.2737 mL	2.5473 mL	6.3684 mL
	20 mM	0.1911 mL	0.9553 mL	1.9105 mL	4.7763 mL
	25 mM	0.1528 mL	0.7642 mL	1.5284 mL	3.8210 mL
	30 mM	0.1274 mL	0.6368 mL	1.2737 mL	3.1842 mL
	40 mM	0.0955 mL	0.4776 mL	0.9553 mL	2.3881 mL
	50 mM	0.0764 mL	0.3821 mL	0.7642 mL	1.9105 mL
	60 mM	0.0637 mL	0.3184 mL	0.6368 mL	1.5921 mL
	80 mM	0.0478 mL	0.2388 mL	0.4776 mL	1.1941 mL
	100 mM	0.0382 mL	0.1911 mL	0.3821 mL	0.9553 mL